212 related articles for article (PubMed ID: 20025993)
1. The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
López-Lázaro M; Willmore E; Austin CA
Mutat Res; 2010 Feb; 696(1):41-7. PubMed ID: 20025993
[TBL] [Abstract][Full Text] [Related]
2. Green tea constituents (-)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide.
López-Lázaro M; Calderón-Montaño JM; Burgos-Morón E; Austin CA
Mutagenesis; 2011 Jul; 26(4):489-98. PubMed ID: 21382914
[TBL] [Abstract][Full Text] [Related]
3. Cells lacking DNA topoisomerase II beta are resistant to genistein.
López-Lazaro M; Willmore E; Austin CA
J Nat Prod; 2007 May; 70(5):763-7. PubMed ID: 17411092
[TBL] [Abstract][Full Text] [Related]
4. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Jobson A; Gilroy KL; Curtis H; Padget K; Austin CA
J Nat Prod; 2007 Dec; 70(12):1884-8. PubMed ID: 18076140
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the clastogenic, DNA intercalative, and topoisomerase II-interactive properties of bioflavonoids in Chinese hamster V79 cells.
Snyder RD; Gillies PJ
Environ Mol Mutagen; 2002; 40(4):266-76. PubMed ID: 12489117
[TBL] [Abstract][Full Text] [Related]
6. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
[TBL] [Abstract][Full Text] [Related]
7. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
8. Flavonoids as DNA topoisomerase antagonists and poisons: structure-activity relationships.
Constantinou A; Mehta R; Runyan C; Rao K; Vaughan A; Moon R
J Nat Prod; 1995 Feb; 58(2):217-25. PubMed ID: 7769390
[TBL] [Abstract][Full Text] [Related]
9. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
10. Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.
López-Lázaro M; Willmore E; Elliott SL; Austin CA
Int J Cancer; 2008 Nov; 123(9):2217-21. PubMed ID: 18712718
[TBL] [Abstract][Full Text] [Related]
11. Dietary factors and the risk for acute infant leukemia: evaluating the effects of cocoa-derived flavanols on DNA topoisomerase activity.
Lanoue L; Green KK; Kwik-Uribe C; Keen CL
Exp Biol Med (Maywood); 2010 Jan; 235(1):77-89. PubMed ID: 20404022
[TBL] [Abstract][Full Text] [Related]
12. Chromosomal malsegregation and micronucleus induction in vitro by the DNA topoisomerase II inhibitor fisetin.
Olaharski AJ; Mondrala ST; Eastmond DA
Mutat Res; 2005 Apr; 582(1-2):79-86. PubMed ID: 15781213
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II inhibition and high yield of endoreduplication induced by the flavonoids luteolin and quercetin.
Cantero G; Campanella C; Mateos S; Cortés F
Mutagenesis; 2006 Sep; 21(5):321-5. PubMed ID: 16950806
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of benzo[a]phenazine derivatives as a dual inhibitor of topoisomerase I and II.
Zhuo ST; Li CY; Hu MH; Chen SB; Yao PF; Huang SL; Ou TM; Tan JH; An LK; Li D; Gu LQ; Huang ZS
Org Biomol Chem; 2013 Jun; 11(24):3989-4005. PubMed ID: 23657605
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.
Salerno S; Da Settimo F; Taliani S; Simorini F; La Motta C; Fornaciari G; Marini AM
Curr Med Chem; 2010; 17(35):4270-90. PubMed ID: 20939813
[TBL] [Abstract][Full Text] [Related]
16. A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.
Kao YH; Hsieh HP; Chitlimalla SK; Pan WY; Kuo CC; Tsai YC; Lin WH; Chuang SE; Chang JY
Anticancer Drugs; 2008 Feb; 19(2):151-8. PubMed ID: 18176111
[TBL] [Abstract][Full Text] [Related]
17. Emodin triggers DNA double-strand breaks by stabilizing topoisomerase II-DNA cleavage complexes and by inhibiting ATP hydrolysis of topoisomerase II.
Li Y; Luan Y; Qi X; Li M; Gong L; Xue X; Wu X; Wu Y; Chen M; Xing G; Yao J; Ren J
Toxicol Sci; 2010 Dec; 118(2):435-43. PubMed ID: 20855424
[TBL] [Abstract][Full Text] [Related]
18. Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Pan X; Hartley JM; Hartley JA; White KN; Wang Z; Bligh SW
Phytomedicine; 2012 May; 19(7):618-24. PubMed ID: 22402246
[TBL] [Abstract][Full Text] [Related]
19. The dietary anticancer agent ellagic acid is a potent inhibitor of DNA topoisomerases in vitro.
Constantinou A; Stoner GD; Mehta R; Rao K; Runyan C; Moon R
Nutr Cancer; 1995; 23(2):121-30. PubMed ID: 7644381
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 7-alkylamino substituted benzo[a]phenazin derivatives as dual topoisomerase I/II inhibitors.
Yao BL; Mai YW; Chen SB; Xie HT; Yao PF; Ou TM; Tan JH; Wang HG; Li D; Huang SL; Gu LQ; Huang ZS
Eur J Med Chem; 2015 Mar; 92():540-53. PubMed ID: 25599951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
